Skip to content

EFFECT OF ORAL ADMINISTRATION OF OLEASELECT TO HUMAN HEALTHY VOLUNTEERS ON METABOLIC AND INFLAMMATORY PATHWAYS RELATED TO THE RISK OF ISCHEMIC CARDIOVASCULAR DISEASE: A PILOT STUDY - ND

EFFECT OF ORAL ADMINISTRATION OF OLEASELECT TO HUMAN HEALTHY VOLUNTEERS ON METABOLIC AND INFLAMMATORY PATHWAYS RELATED TO THE RISK OF ISCHEMIC CARDIOVASCULAR DISEASE: A PILOT STUDY - ND

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2008-003991-23-IT
Enrollment
Unknown
Registered
2008-07-21
Start date
2008-11-05
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inadequate diet for protective factors for vascular system MedDRA version: 9.1 Level: LLT Classification code 10021577 Term: Inadequate diet

Interventions

Product Name: OLEASELECT Pharmaceutical Form: Tablet Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 250- Pharmaceutical form of the placebo: Tablet Route of admini

Sponsors

POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 18-65 age healthy volunteers if their dietary habits will correspond to the lowest values (Iowest tertile) of the score measuring the adherence to the Mediterranean diet Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: vegetarian, pregnant women, history of previous cardiovascular disease, severe hypertension (SBP>180 and/or DBP >110 mmHG), severe diabetes (blood glucose >250 mg/dl), severe dyslipidemia (Chol > 350 mg/dl or TG> 400 mg/dl), body mass index (in kg/m2) >35, major diseases, chronic use of drugs or use of drugs in the 2 weeks prior to the inclusion into the study.

Design outcomes

Primary

MeasureTime frame
Main Objective: to assess the feasibility of a clinical trial to establish the ability of OleaSelect after repeated oral administration to influence metabolic pathways related to atherosclerosis and thrombosis and their response to a stress condition such as a fat meal in healthy human subjects.;Secondary Objective: nd;Primary end point(s): nd

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026